PubMed:23184608 / 604-720 JSONTXT

{"project":"c_corpus","denotations":[{"id":"T73","span":{"begin":8,"end":14},"obj":"D009369"},{"id":"T74","span":{"begin":8,"end":14},"obj":"D009369"},{"id":"T77","span":{"begin":48,"end":58},"obj":"C562366"},{"id":"T78","span":{"begin":48,"end":58},"obj":"C562366"},{"id":"T79","span":{"begin":73,"end":77},"obj":"PR:P15379"},{"id":"T80","span":{"begin":73,"end":77},"obj":"PR:P26051"},{"id":"T81","span":{"begin":73,"end":77},"obj":"PR:000001307"},{"id":"T82","span":{"begin":73,"end":77},"obj":"PR:P16070"},{"id":"T83","span":{"begin":89,"end":99},"obj":"D000906"}],"text":"control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs."}

{"project":"UseCases_ArguminSci_Discourse","denotations":[{"id":"T8","span":{"begin":0,"end":116},"obj":"DRI_Background"}],"text":"control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs."}